Bristol-Myers Squibb Company
NYSEBristol-Myers Squibb has cleared Q2 and the setup has flipped — the shorts that were rebuilding ahead of the July 30 print are now unwinding, while a wave of analyst upgrades and target hikes is pushing the stock to $65.89, up 13% over the past month. The short interest reversal is direct confirmation of what that pre-earnings rebuild was: a hedged bet into results, not a structural…
BMY short interest surged 21% over one week to 2.35% of free float, highest level in 30 days, as shorts rebuild aggressively post-earnings despite loose borrow conditions and 7,407% availability.
Bristol-Myers Squibb has cleared Q2 and the setup has flipped — the shorts that were rebuilding ahead of the July 30 print are now unwinding, while a wave of analyst upgrades and target hikes is pushing the stock to…
Bristol-Myers Squibb reports Q2 earnings on July 30 with the stock at $63.60 and options traders notably relaxed — yet short interest has just posted its sharpest weekly jump in months, creating a quiet tension under…
Snapshot as of 6 Aug 2026
Bristol-Myers Squibb reports second-quarter results on July 30 with the stock riding its strongest stretch in months, but the debate heading into the print centres on whether a rebuilt pipeline can replace the revenue…
Bristol-Myers Squibb heads into its July 30 earnings print with options positioning unusually skewed toward calls — a notable shift for a stock that has otherwise drifted quietly lower. The clearest signal this week is…
The short build in Bristol-Myers Squibb has continued at pace since Tuesday's note. Short interest now stands at 2.32% of free float — up another 20.8% in a single week and 60% over the past month. Bears that were…
Bristol-Myers Squibb enters the first week of June in an uncomfortable spot: the stock has shed 6.2% over the past week and 6.5% over the past month, while short sellers have been quietly rebuilding positions at the…
Bristol-Myers Squibb heads into the back half of May with two competing stories pulling in opposite directions: a strategic AI deal with Anthropic announced today, and the fastest build in short interest the stock has…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BMY — free to start on ORTEX.
Sign up for free →Open BMY on ORTEX